Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Aurinia Pharmaceuticals Rose as Much as 10.8% This Morning

By Maxx Chatsko - Apr 7, 2017 at 1:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Management updated investors on development plans for the company's lead drug candidate.

What happened

Shares of clinical-stage drug developer Aurinia Pharmaceuticals (AUPH 0.69%) rose nearly 11% Friday morning after the company announced plans for the development of its lead drug candidate, voclosporin, in treating lupus nephritis. Management met separately with the European Medicines Agency (EMA) and Japan's Pharmaceutical and Medical Devices Agency (PMDA) to discuss what data were needed in a successful phase 3 trial to potentially gain marketing approval.

Good news: Aurinia Pharmaceuticals announced that a single phase 3 trial can be used to collect data that will be sufficient to submit to regulators in the European Union, Japan, and the United States. As of 1:30 p.m. EDT, the microcap stock had settled down to a 6% gain.

A businessman drawing a stock chart symbolizing growth.

Image source: Getty Images.

So what

If each region had set different data standards, then the company may have needed to run multiple trials with varying designs. That would have been more expensive than running a single trial. Or, as may have been the case for a pre-revenue company such as Aurinia Pharmaceuticals, it would have been forced to choose a region to focus on initially while postponing development in others. Luckily, that won't be the case.

The ability to run a single trial swipes away a good deal of development uncertainty and provides a clear path for the company and investors, who can focus on a single phase 3 trial. Management even released the trial design, which includes the following highlights:

  • A 52-week, double-blind study enrolling 320 patients.
  • Randomized enrollment with one arm receiving 23.7 mg of voclosporin and standard treatment, and the other arm receiving placebo and standard treatment.
  • The primary efficacy endpoint will be complete remission, or renal response, at 52 weeks, which has set measuring thresholds.

It's important to note that the 23.7 mg dose of voclosporin was found to elicit the best response in patients in the recently completed phase 2b trial. If the proposed phase 3 trial can achieve similar safety and efficacy results to the mid-stage study, then the drug candidate should have no problem gaining approval on the three continents.

Now what

Aurinia Pharmaceuticals stock has soared 195% in the last three months on a string of favorable catalysts. Unfortunately for investors, they may be coming to an end in the near term as the company focuses on enrolling patients and conducting the trial. There really isn't much investors can do other than wait for the 52-week trial to be initiated and then completed.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
$10.28 (0.69%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.